Enrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660, Dolasynthen B7-H4 ADC; expect to initiate expansion in Q2 2024 and announce initial clinical data in mid-2024
Phase 1 clinical trial of XMT-2056, Immunosynthen HER2 ADC, restarting; plan to advance dose escalation in 2024
Expect capital resources will support current operating plan commitments into 2026
Company to webcast presentation from 42nd Annual J.P. Morgan Healthcare Conference at 2:15 p.m. Eastern Time (ET)/11:15 a.m. Pacific Time (PT) on January 11, 2024
https://www.globenewswire.com/news-release/2024/01/05/2804621/0/en/Mersana-Therapeutics-Announces-Business-Updates-Expected-2024-Milestones-and-Upcoming-Presentation-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html
